Answers are grounded in this paper and cite their sources.
, reduced airway smooth muscle mass in patients with asthma by decreasing airway eosinophilia in concert with reduced recruitment of myofibroblasts and fibrocytes to the airway smooth muscle bundle. Fevipiprant may thus represent a potential therapy to ameliorate airway remodeling in asthma.
No takes yet. Share an insight, caveat, or question.
Saunders et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: